Study Overview: This study checks how well a new drug called deucravacitinib works for people with Systemic Lupus Erythematosus (SLE), a condition where the immune system attacks the body. The study compares deucravacitinib to a placebo, a pill with no medicine in it, to see if it's safe and effective.

Eligibility: To join, you need to have been diagnosed with SLE at least 24 weeks before joining. You must meet certain health criteria like having specific antibodies in your blood or a certain disease activity score. Some medications like immunosuppressants should be on a stable dose for weeks before starting the study.

Exclusions: You cannot join if you have drug-induced SLE, other autoimmune diseases, or other specific health conditions, like active severe lupus nephritis or active infections.

• Study involves multiple visits over a period of time.
• You may receive compensation for participation.
• Potential side effects and risks will be explained during the study.

Deciding to join a study is important, so think about the visits, possible benefits, and risks before participating.